Loading...
NGEN logo

NervGen Pharma Corp.TSXV:NGEN Stock Report

Market Cap CA$398.2m
Share Price
CA$5.15
CA$7.48
31.2% undervalued intrinsic discount
1Y87.3%
7D-8.2%
1D
Portfolio Value
​
View

NervGen Pharma Corp.

TSXV:NGEN Stock Report

Market Cap: CA$398.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NervGen Pharma (NGEN) Stock Overview

A biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. More details

NGEN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Earnings are forecast to grow 63.77% per year

Analysts in good agreement that stock price will rise by 45.3%

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue (CA$0)

Significant insider selling over the past 3 months


NGEN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

NervGen Pharma Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for NervGen Pharma
Historical stock prices
Current Share PriceCA$5.15
52 Week HighCA$8.49
52 Week LowCA$2.57
Beta0.86
1 Month Change-10.28%
3 Month Change-11.21%
1 Year Change87.27%
3 Year Change215.95%
5 Year Change182.97%
Change since IPO195.98%

Recent News & Updates

Recent updates

Analysis Article • Oct 23

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 11

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 22

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Aug 30

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 04

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Feb 02

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Key Insights NervGen Pharma's estimated fair value is CA$3.2 based on 2 Stage Free Cash Flow to Equity Current share...
Analysis Article • Nov 23

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 29

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 16

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 08

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

NGENCA PharmaceuticalsCA Market
7D-8.2%7.3%0.4%
1Y87.3%65.5%32.9%

Return vs Industry: NGEN exceeded the Canadian Pharmaceuticals industry which returned 24% over the past year.

Return vs Market: NGEN exceeded the Canadian Market which returned 31.1% over the past year.

Price Volatility

Is NGEN's price volatile compared to industry and market?
NGEN volatility
NGEN Average Weekly Movement8.9%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement10.2%
10% most volatile stocks in CA Market17.7%
10% least volatile stocks in CA Market3.8%

Stable Share Price: NGEN has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: NGEN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aAdam Rogersnervgen.com

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.

NervGen Pharma Corp. Fundamentals Summary

How do NervGen Pharma's earnings and revenue compare to its market cap?
NGEN fundamental statistics
Market capCA$398.25m
Earnings (TTM)-CA$25.57m
Revenue (TTM)n/a
0.0x
P/S Ratio
-16.0x
P/E Ratio

Is NGEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NGEN income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$25.57m
Earnings-CA$25.57m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NGEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/16 15:26
End of Day Share Price 2026/03/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NervGen Pharma Corp. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Elemer PirosLucid Capital Markets
Michael OkunewitchMaxim Group